# US 2008/0305476 A1 · Immunoassay Methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305476 A1
- Document ID: US20080305476A1
- Status: Published application
- Kind: A1
- Application number: 11/814,516
- Filed: 2006-05-26
- Published: 2008-12-11
- Earliest claimed: 2005-05-27
- Assignees: Onc-Immune Ltd.
- Inventors: John Forsyth Russell Robertson; Anthony Barnes; Andrea Murray; Caroline Chapman
- Web page: https://patentgrep.com/patent/US20080305476A1

## CPC

- G01N 33/575: for cancer
- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 2800/102: Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to a method of detecting a disease state or disease susceptibility in a mammalian subject which comprises detecting an antibody in a test sample comprising a bodily fluid from said mammalian subject wherein said antibody is a biological marker of a disease state or disease susceptibility, the method comprising: (a) contacting said test sample with a plurality of different amounts of an antigen specific for said antibody, (b) detecting the amount of specific binding between said antibody and said antigen, (c) plotting or calculating a curve of the amount of said specific binding versus the amount of antigen for each amount of antigen used in step (a) and (d) determining the presence or absence of said disease state or disease susceptibility based upon the amount of specific binding between said antibody and said antigen at each different antigen concentration used.

## Claims

### Claim 1

A method of detecting a disease state or disease susceptibility in a mammalian subject, comprising detecting an antibody in a test sample comprising a bodily fluid from said mammalian subject wherein said antibody is a biological marker of a disease state or disease susceptibility, the method comprising:
(a) contacting said test sample with a plurality of different amounts of an antigen specific for said antibody,
(b) detecting the amount of specific binding between said antibody and said antigen,
(c) plotting or calculating a curve of the amount of said specific binding versus the amount of antigen for each amount of antigen used in step (a) and
(d) determining the presence or absence of said disease state or disease susceptibility based upon the amount of specific binding between said antibody and said antigen at each different antigen concentration used.

### Claim 2 (depends on 1)

The method of claim 1 wherein the presence or absence of said disease state or disease susceptibility is determined based upon the collective values of the amount of specific binding for the antigen concentrations tested.

### Claim 3 (depends on 1)

The method of claim 1 wherein the presence or absence of said disease state or disease susceptibility is determined by screening the plot of step (c) for the presence of a generally S-shaped or sigmoidal curve.

### Claim 4 (depends on 1)

The method of claim 1 wherein the antibody is an autoantibody specific for a tumour marker protein.

### Claim 5 (depends on 4)

The method of claim 4 wherein the antigen is a tumour marker protein or an antigenic fragment or epitope thereof.

### Claim 6 (depends on 5)

The method of claim 5 wherein the tumour marker protein is MUC1, MUC16, c-myc, EGRF, p53, ras, BRCA1, BRCA2, APC, HER2, PSA, CEA, CA19.9, NY-ESO-1, 4-5, CAGE, PSMA, PSCA, EpCam, a cytokeratin, recoverin, a kallikrein, an annexin, AFP, GRP78, CA125, mammoglobin, or raf.

### Claim 7 (depends on 4)

Use of the method of claim 4 in the diagnosis, prognosis or monitoring of cancer.

### Claim 8 (depends on 4)

Use of the method of claim 4 in screening a population of asymptomatic human subjects to identify those subjects who are at increased risk of developing cancer, wherein the samples to be tested using the method are samples of bodily fluid taken from the subjects, and wherein subjects having an elevated level of autoantibodies, as compared to normal control individuals, are identified as being at risk of developing cancer.

### Claim 9 (depends on 4)

Use of the method of claim 4 in detecting early neoplastic or early carcinogenic change in an asymptomatic human subject, wherein the sample to be tested using the method is a sample of bodily fluid taken from the subject, and wherein the presence of an elevated level of autoantibodies, as compared to normal control individuals, is taken as an indication of early neoplastic or early carcinogenic change in the subject.

### Claim 10 (depends on 4)

Use of the method of claim 4 in screening a population of asymptomatic human subjects to identify those subjects who have developed a cancer, wherein the samples to be tested using the method are samples of bodily fluid taken from the subjects, and wherein subjects having an elevated level of autoantibodies, as compared to normal control individuals, are diagnosed as having a cancer.

### Claim 11 (depends on 4)

Use of the method of claim 4 in testing a population of symptomatic human subjects to identify those subjects who have developed a cancer, wherein the samples to be tested using the method are samples of bodily fluid taken from the subjects, and wherein subjects having an elevated level of autoantibodies, as compared to normal control individuals, are diagnosed as having a cancer.

### Claim 12 (depends on 4)

Use of the method of claim 4 in monitoring the progress of cancer or other neoplastic disease in a patient, wherein the sample to be tested using the method is a sample of bodily fluid taken from a human patient, and wherein the presence of an elevated level of autoantibodies, as compared to a normal control, is taken as an indication of the presence of cancer in the patient.

### Claim 13 (depends on 4)

Use of the method of claim 4 in the detection of recurrent disease in a human patient previously diagnosed as having cancer, which patient has undergone anti-cancer treatment to reduce the amount of cancer present, wherein the sample to be tested using the method is a sample of bodily fluid taken from the patient, and wherein the presence of an increased level of autoantibodies in the patient, as compared to a normal control, is taken as an indication that disease has recurred.

### Claim 14 (depends on 4)

Use of the method of claim 4 in assessment of prognosis from cancer, wherein the sample to be tested using the method is a sample of bodily fluid taken from a human patient, and wherein the presence of an elevated level of autoantibodies, as compared to a normal control, is taken as an indication of the prognosis of the patient from their cancer.

### Claim 15 (depends on 4)

Use of the method of claim 4 in predicting response to anti-cancer treatment, wherein the sample to be tested using the method is a sample of bodily fluid taken from a human patient, and wherein comparison of the level of autoantibodies is said patient with a previously established relationship between levels of autoantibodies and likely outcome of treatment is used to provide an indication of whether the patient will respond to such anti-cancer treatment.

### Claim 16 (depends on 15)

Use according to claim 15 wherein the anti-cancer treatment is vaccination, anti-growth factor or signal transduction therapy, radiotherapy, endocrine therapy, human antibody therapy or chemotherapy.

### Claim 17 (depends on 4)

Use of the method of claim 4 in monitoring the response of a human cancer patient to anti-cancer treatment, wherein the sample to be tested using the method is a sample of bodily fluid taken from the patient, and wherein a change in the level of autoantibodies after treatment is taken as an indication of whether or not the patient has responded to the treatment.

### Claim 18 (depends on 17)

Use according to claim 17 wherein the treatment is vaccination, anti-growth factor or signal transduction therapy, radiotherapy, endocrine therapy, human antibody therapy or chemotherapy and a change in the level of autoantibodies after treatment is taken as an indication that the patient has responded positively to the treatment.

### Claim 19 (depends on 4)

Use of the method steps (a) to (c) of claim 4 in the selection of an anti-cancer treatment for use in a particular human patient, wherein the method is carried out using a panel of two or more antigens each corresponding to a different tumour marker protein in order to determine the relative strength of the patient's immune response to each of the different tumour marker proteins, wherein the tumour marker protein or proteins identified as eliciting the strongest immune response or strong responses in the patient is or are selected to form the basis of an anti-cancer treatment for use in said patient.

### Claim 20 (depends on 19)

Use according to claim 19 wherein the anti-cancer treatment is vaccination and the tumour marker protein or proteins identified as eliciting the strongest immune response or strong responses in the patient is or are selected to form the basis of an anti-cancer vaccine for use in said patient.

### Claim 21 (depends on 1)

The method of claim 1 wherein the antibody is an autoantibody characteristic of or associated with an autoimmune disease.

### Claim 22 (depends on 21)

The method of claim 21 wherein the autoimmune disease is rheumatoid arthritis, systemic lupus erythematous (SLE), primary biliary cirrhosis (PBC), autoimmune thyroiditis, Hashimoto's thyroiditis, autoimmune gastritis, pernicious anaemia, autoimmune adrenalitis, Addison's disease, autoimmune hypoparathyroidism, autoimmune diabetes or myasthenia gravis.

### Claim 23 (depends on 1)

The method of claim 1 wherein the antibody is an autoantibody characteristic of or associated with kidney or hepatic disease leading to insufficiency or failure of either organ.

### Claim 24 (depends on 1)

The method of claim 1 wherein the antibody is directed towards an epitope present on tissue transplanted into the mammalian subject.

### Claim 25

A method of detecting an antibody in a test sample comprising a bodily fluid from a mammalian subject, wherein said antibody is directed to a foreign substance introduced into said mammalian subject, the method comprising:
(a) contacting the test sample with a plurality of different amounts of an antigen specific for said antibody,
(b) detecting the amount of specific binding between said antibody and said antigen, and
(c) plotting or calculating a curve of the amount of said specific binding versus the amount of antigen for each amount of antigen used in step (a).

### Claim 26 (depends on 25)

The method of claim 25 further comprising detecting the presence of said antibody based upon the amount of specific binding between said antibody and said antigen at the different antigen concentrations used.

### Claim 27 (depends on 25)

The method of claim 25 wherein detecting the presence of said antibody is based upon the collective values of the amount of specific binding for the antigen concentrations tested.

### Claim 28 (depends on 25)

The method of claim 25 wherein the presence in the test sample of antibody reactive with the antigen used in the assay in indicated by a generally S-shaped or sigmoidal curve.

### Claim 29 (depends on 25)

The method of claim 25 wherein the mammalian subject is a human.

### Claim 30 (depends on 25)

The method of claim 25 wherein the foreign substance is a therapeutic agent.

### Claim 31 (depends on 30)

The method of claim 30 wherein the therapeutic agent is a drug, prodrug, or antibody therapy.

### Claim 32 (depends on 25)

The method of claim 25 wherein the foreign substance is a vaccine.

### Claim 33 (depends on 31)

The method of claim 31 wherein the foreign substance is a non-target portion of a therapeutic agent or vaccine.

### Claim 34 (depends on 33)

The method of claim 33 wherein the non-target portion is biotin.

### Claim 35 (depends on 25)

The method of claim 25 wherein the foreign substance is an infectious agent such as fungus, bacteria, virus or parasite.

### Claim 36

A method of detecting an antibody in a test sample comprising a bodily fluid from a mammalian subject wherein said antibody is a biological marker of a disease state or disease susceptibility, the method comprising:
a) contacting the test sample with a plurality of different amounts of an antigen specific for said antibody,
b) detecting the amount of specific binding between said antibody and said antigen and
c) plotting or calculating a curve of the amount of said specific binding versus the amount of antigen for each amount of antigen used in step (a).

### Claim 37 (depends on 36)

The method of claim 36 wherein the presence in the test sample of antibody reactive with the antigen used in the assay is indicated by a generally S-shaped or sigmoidal curve.

### Claim 38 (depends on 36)

The method of claim 36 wherein the antibody is an autoantibody specific for a tumour marker protein.

### Claim 39 (depends on 36)

The method of claim 36 wherein the antigen is a tumour marker protein or an antigenic fragment or epitope thereof.

### Claim 40 (depends on 39)

The method of claim 39 wherein the tumour marker protein is MUC1, MUC16, c-myc, EGRF, p53, ras, BRCA1, BRCA2, APC, HER2, PSA, CEA, CA19.9, NY-ESO-1, 4-5, CAGE, PSMA, PSCA, EpCam, a cytokeratin, recoverin, a kallikrein, an annexin, AFP, GRP78, CA125, mammoglobin, or raf.

### Claim 41 (depends on 36)

The use of the method of claim 36 in the diagnosis, prognosis or monitoring of cancer.

### Claim 42 (depends on 8, 36)

The use of the method of claim 36 for the application of claim 8.

### Claim 43 (depends on 36)

The method of claim 36 wherein the antibody is an autoantibody characteristic of or associated with an autoimmune disease.

### Claim 44 (depends on 36)

The method of claim 36 wherein the autoantibody is an autoantibody characteristic of or associated with a disease leading to insufficiency or failure of an organ.

### Claim 45 (depends on 44)

The method of claim 44 wherein the disease is kidney or hepatic disease.

### Claim 46 (depends on 36)

The method of claim 36 wherein the antibody is directed towards an epitope present or tissue transplanted into a mammalian subject.

### Claim 47 (depends on 36)

The method of claim 36 wherein the antigen is a naturally occurring protein or polypeptide, a recombinant protein or polynucleotide, a synthetic protein or polypeptide, synthetic peptide, peptide mimetic, polysaccharide or nucleic acid.
